North America Biobanking Market to hit US$ 2.27 Billion by 2033 | Top Companies - Thermo Fisher Scientific Inc., QIAGEN N.V., Merck KGaA

Leander, Texas and Tokyo, Japan - Dec.12.2025
As per DataM intelligence research report" The North America biobanking market reached US$1.09 billion in 2024 and is expected to reach US$2.27 billion by 2033, growing at a CAGR of 8.6% during the forecast period 2025-2033" Precision medicine and increased genomic research are fueling rapid growth in biobanking infrastructure.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/north-america-biobanking-market?prasad

North America: Recent Industry Developments

✅ In November 2025, The NIH "All of Us" research program released a new cloud-based portal for biobank access The portal allows researchers to query genomic and phenotypic data from one million diverse participants It democratizes access to massive biological datasets for U.S. scientists

✅ In October 2025, Azenta Life Sciences launched an automated cryogenic storage system with AI monitoring The system predicts equipment failure to prevent sample loss in high-value biobanks It ensures the integrity of irreplaceable biological assets in the U.S.

✅ In September 2025, Mayo Clinic partnered with a tech firm to digitize its pathology biobank The project uses AI to scan and index millions of tissue slides for virtual analysis It transforms physical archives into a searchable digital resource for U.S. cancer research

✅ In August 2025, The FDA issued final guidance on the informed consent process for banking human tissues The guidance clarifies the rules for using leftover clinical samples in research It streamlines the regulatory compliance for U.S. hospital-based biobanks

Japan: Recent Industry Developments

✅ In December 2025, The Tohoku Medical Megabank Organization completed the sequencing of 150,000 residents The biobank integrated genomic data with long-term health records to study disaster-related health impacts It serves as a global model for large-scale population cohorts

✅ In November 2025, The National Cancer Center Japan launched a "Liquid Biopsy Biobank" The repository collects serial blood samples from cancer patients undergoing immunotherapy It supports the development of non-invasive diagnostics by Japanese pharma companies

✅ In October 2025, RIKEN BioResource Research Center expanded its iPS cell bank with HLA-homozygous lines The expansion increases the availability of immunologically compatible cells for regenerative medicine It accelerates the clinical application of cell therapies in Japan

✅ In September 2025, Kyoto University Hospital implemented an automated robotic retrieval system for its biobank The system retrieves samples at -80°C without exposing them to ambient temperatures It improves sample quality for sensitive proteomic and metabolomic research

North America Biobanking Market: Drivers
North America's biobanking sector is advancing rapidly due to increased genomic research, precision medicine initiatives, and demand for high-quality biospecimen management. Government-backed healthcare programs and collaborations between hospitals, research institutes, and biotech firms are strengthening infrastructure. Biobanks are playing a crucial role in cancer research, regenerative medicine, and rare disease studies.

New technologies, including automated sample handling, AI-driven data analytics, and cloud-based biorepositories, are enhancing efficiency and traceability. The region is witnessing rising investments in long-term biological sample preservation and standardized biobanking protocols. Ethical frameworks and data governance rules are also evolving to ensure responsible use of biological data. This sustained innovation is positioning North America as a global leader in biobanking advancements.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/north-america-biobanking-market?prasad

North America Biobanking Market: Major Players
Thermo Fisher Scientific Inc., QIAGEN N.V., PHC Corporation, Merck KGaA, Avantor, Inc., Cryoport Systems, LLC., Tecan Group Ltd., Azenta US Inc., Greiner Bio-One North America Inc., Hamilton Company and among others.

Segment Covered in the North America Biobanking Market:
By Specimen Type
The market is segmented into blood 40%, tissues 25%, cell lines 15%, nucleic acids 10%, and others 10%. Blood dominates due to its extensive use in clinical research, genomics, biomarker discovery, and disease surveillance. Tissue samples continue strong adoption for oncology research and pathology applications. Cell lines support drug discovery and toxicity studies, while nucleic acids gain traction with rising genomic and precision medicine initiatives. Growing demand for high-quality, well-annotated specimens drives overall market expansion.

By Product & Services
The market includes equipment 35%, consumables 30%, services 25%, and software 10%. Equipment leads due to high installation of cryogenic storage systems, freezers, refrigerators, and sample handling instruments. Consumables such as vials, tubes, reagents, and cryo-bags grow consistently with increasing sample volumes. Biobanking services-including storage, processing, and sample management-are rapidly expanding due to outsourcing trends. Software adoption rises with the need for digitized biobank management, LIMS integration, and data traceability.

By Storage Type
Storage types include manual storage 55% and automated storage 45%. Manual storage dominates among small and mid-sized biobanks due to lower cost and flexible setup. However, automated storage is growing rapidly as large biobanks and pharmaceutical companies adopt robotics for high-throughput sample handling, enhanced security, and error-free tracking. The shift toward automated, temperature-controlled systems supports long-term sample integrity and scalability.

By Application
Applications include therapeutic research 25%, life science research 20%, regenerative medicine 18%, clinical diagnostics 15%, personalized medicine 12%, and others 10%. Therapeutic research leads due to rising demand for samples in oncology, infectious diseases, and chronic disease studies. Life science research benefits from large-scale genomic, proteomic, and biomarker projects. Regenerative medicine applications grow with stem cell banking and engineered tissue studies. Personalized medicine expands as precision diagnostics and patient-specific therapies gain adoption across North America.

By End-User
End-users include pharmaceutical and biotechnology companies 40%, academic and research institutes 30%, hospitals and clinics 20%, and others 10%. Pharmaceutical and biotechnology companies dominate due to extensive use of biobanks for drug discovery, clinical trials, and biomarker development. Academic institutes contribute significantly with research programs and sample repositories. Hospitals and clinics increase participation through patient sample collections and diagnostic biobanking initiatives.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=north-america-biobanking-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.